作者
Paola Ghione, Erel Joffe, Nadia De Paola, Timothy Mainardi, Sarah J Noor, Sabela Bobillo, Patricia L Myskowski, M Lia Palomba, Alison J Moskowitz, Anthony R Mato, Fushen Sha, Gottfried Von Keudell, David J Straus, Ariela Noy, Anas Younes, Paul A Hamlin, Renier J Brentjens, Miguel Angel Tejedor-Alonso, Steven M Horwitz, Andrew David Zelenetz
发表日期
2020/5/20
来源
Journal of Clinical Oncology
卷号
38
期号
15_suppl
页码范围
8062-8062
出版商
American Society of Clinical Oncology
简介
8062
Background: Immunotherapy with anti CD20 is often associated with mild easily manageable infusion reactions. In rare cases, patients experience severe drug hypersensitivity reactions (DHR) serum sickness or anaphylaxis. These in turn may lead to discontinuation of the drug. In our experience, switching to a different anti-CD20 agent is a feasible alternative to discontinuation or desensitization protocols. Methods: From our pharmacology database we identified all the patients that received rituximab and/or obinutuzumab, and/or ofatumumab, and/or all the patients who received a flat dose of less than 50 mL of the same drugs and were followed at our institution. From the medical record, we identified all the cases where the anti-CD20 antibody was changed due to allergy, serum sickness or other types of DHR, and all those who received minimal doses of anti-CD20 in the context of a desensitization protocol …
学术搜索中的文章
P Ghione, E Joffe, N De Paola, T Mainardi, SJ Noor… - 2020